Home/Biosimilar Atlas/Companies/Eris Lifesciences

Eris Lifesciences

Biosimilar developer, India. 2 development products across 2 molecules: insulin glargine, insulin human.

First approval in the Atlas: Dec 2025, Eris Lifesciences (INN only), insulin glargine (CDSCO)
FDAproducts approved0
EMAproducts approved0
MHRAproducts approved0
PMDAproducts approved0
HCproducts approved0
CDSCOproducts approved2
EDEproducts registered0
Connections
2molecules2products1 of 7markets0candidates in trials3companies on the same molecules

Portfolio by market

MoleculeProductFDAEMAMHRAPMDAHCCDSCOEDEMarkets
Insulin glargineEris insulin glargine·····Dec 2025·1/7
Insulin humanEris human insulin·····Dec 2025·1/7

Month shown is the first approval or registration of that product in that market.

Companies on the same molecules

Developers whose portfolios overlap most with Eris Lifesciences, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.

Biocon BiologicsTwo shared molecules: insulin glargine, insulin human9 molecules in its portfolioM.J. BiopharmTwo shared molecules: insulin glargine, insulin human2 molecules in its portfolioRegenixTwo shared molecules: insulin glargine, insulin human2 molecules in its portfolio

Chronology

Compare Eris Lifesciences with other developers on the comparison page.

Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.

Planning your biosimilar strategy?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.